We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

32 hedge funds and large institutions have $137M invested in Sutro Biopharma in 2018 Q3 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

5.24% more ownership

Funds ownership: 0% → 5.24% (+5.2%)

Holders
32
Holders Change
+32
Holders Change %
–
% of All Funds
0.73%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
32
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
+$27.6M
2
Citadel Advisors
Citadel Advisors
Florida
+$26.4M
3
EAM
Eventide Asset Management
Massachusetts
+$18.8M
4
CCM
Camber Capital Management
Massachusetts
+$9.06M
5
CI
Cowen Inc
New York
+$6.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SHI
1
SV Health Investors
Massachusetts
$27.4M +$27.6M +182,454 New
Citadel Advisors
2
Citadel Advisors
Florida
$26.2M +$26.4M +174,842 New
EAM
3
Eventide Asset Management
Massachusetts
$18.1M +$18.8M +124,490 New
CCM
4
Camber Capital Management
Massachusetts
$9M +$9.06M +60,000 New
CI
5
Cowen Inc
New York
$6.26M +$6.3M +41,732 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$6M +$6.04M +40,000 New
DCM
7
Driehaus Capital Management
Illinois
$5.37M +$5.41M +35,828 New
BlackRock
8
BlackRock
New York
$5.1M +$5.13M +33,990 New
SFM
9
Sphera Funds Management
Israel
$4.13M +$4.15M +27,500 New
TCM
10
Tekla Capital Management
Massachusetts
$3.75M +$3.77M +25,000 New
SCM
11
Sio Capital Management
New York
$3.49M +$3.51M +23,254 New
NC
12
Nexthera Capital
New York
$3.47M +$3.5M +23,161 New
FCM
13
Farallon Capital Management
California
$2.25M +$2.27M +15,000 New
Jennison Associates
14
Jennison Associates
New York
$2.25M +$2.27M +15,000 New
IBT
15
International Biotechnology Trust
United Kingdom
$1.69M +$2.21M +14,665 New
AIC
16
AWM Investment Company
New York
$1.67M +$1.68M +11,148 New
MIM
17
Monashee Investment Management
Massachusetts
$1.57M – – –
JP Morgan Chase
18
JP Morgan Chase
New York
$1.5M +$1.51M +10,005 New
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$1.5M +$1.51M +10,000 New
OAM
20
Oxford Asset Management
United Kingdom
$1.2M +$1.21M +7,986 New
Millennium Management
21
Millennium Management
New York
$1.15M +$1.16M +7,666 New
PCM
22
Pentwater Capital Management
Florida
$1.05M +$1.06M +7,000 New
Wellington Management Group
23
Wellington Management Group
Massachusetts
$715K +$720K +4,765 New
DIM
24
DC Investments Management
Virginia
$592K +$596K +3,947 New
Goldman Sachs
25
Goldman Sachs
New York
$425K +$427K +2,830 New
1
2

STRO Hedge Fund Activity: Q3 2018 in Review

32 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2018, worth a combined $137M.

Buyers outnumbered sellers: 32 funds opened new STRO positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was SV Health Investors, opening a new position worth an estimated $27.6M.

  • 32 institutional investors held Sutro Biopharma (STRO) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $137M of Sutro Biopharma stock for Q3 2018.
  • 32 funds opened new Sutro Biopharma positions in Q3 2018 and 0 closed out, a net change of +32 holders.
  • The largest Sutro Biopharma buyer in Q3 2018 was SV Health Investors, an estimated $27.6M added.

Based on aggregated 13F filings for Q3 2018.